Computational fragment-based drug design of potential Glo-I inhibitors

References

• Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res. 2007;67(8):3500–3504.
   PubMed Web of Science ®Google Scholar
• Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J. Cancer: a systems biology disease. Biosystems. 2006;83(2-3):81–90.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B, Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–2116.
   PubMed Web of Science ®Google Scholar
• Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141–162.
   PubMed Web of Science ®Google Scholar
• Vince R, Wadd WB. Glyoxalase inhibitors as potential anticancer agents. Biochem Biophys Res Commun. 1969;35(5):593–598.
   PubMed Web of Science ®Google Scholar
• Racker E. The mechanism of action of glyoxalase. J Biol Chem. 1951;190(2):685–696.
   PubMed Web of Science ®Google Scholar
• Sousa Silva M, Gomes RA, Ferreira AEN, Ponces Freire A, Cordeiro C. The glyoxalase pathway: the first hundred years… and beyond. Biochem J. 2013;453(1):1–15.
   PubMedGoogle Scholar
• Dakin HD, Dudley HW. An enzyme concerned with the formation of hydroxy acids from ketonic aldehydes. J Biol Chem. 1913;14(2):155–157.
   Google Scholar
• He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, Diao Q, Zheng Z, Liu D. Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators. Biomedicine and Pharmacotherapy. 2020;131:110663.
   PubMed Web of Science ®Google Scholar
• Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates: investigation using a specific assay for methylglyoxal. Eur J Biochem. 1993;212(1):101–105.
   PubMedGoogle Scholar
• Rulli A, Carli L, Romani R, Baroni T, Giovannini E, Rosi G, Talesa V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res Treat. 2001;66(1):67–72.
   PubMed Web of Science ®Google Scholar
• Chen F, Wollmer MA, Hoerndli F, Münch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Götz J. Role for glyoxalase I in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2004;101(20):7687–7692.
   PubMed Web of Science ®Google Scholar
• Bélanger M, Yang J, Petit JM, Laroche T, Magistretti PJ, Allaman I. Role of the glyoxalase system in astrocyte-mediated neuroprotection. J Neurosci. 2011;31(50):18338–18352.
   PubMed Web of Science ®Google Scholar
• Xue M, Rabbani N, Thornalley PJ. Glyoxalase in ageing. Semin Cell Dev Biol. 2011;22(3):293–301.
   PubMed Web of Science ®Google Scholar
• Vander Jagt DL, Hunsaker LA. Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact. 2003;143-144:341–351.
   PubMed Web of Science ®Google Scholar
• Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, Taniguchi H, Yanagihara K, Imoto I, et al. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene. 2015;34(9):1196–1206.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuramitsu Y, Tokuda K, Okada F, Baron B, Akada J, Kitagawa T, Nakamura K. Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma. Electrophoresis. 2014;35(15):2195–2202.
   PubMed Web of Science ®Google Scholar
• More SS, Vince R. Design, synthesis, and binding studies of bidentate Zn-chelating peptidic inhibitors of glyoxalase-I. Bioorg Med Chem Lett. 2007;17(13):3793–3797.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective Activation of Apoptosis Program by S-p-Bromobenzylglutathione Cyclopentyl Diester in Glyoxalase I-Overexpressing Human Lung Cancer Cells. 2001;7:2513–2518. http://aacrjournals.org/clincancerres/article-pdf/7/8/2513/2080179/df0801002513.pdf.
   Google Scholar
• Mearini E, Romani R, Mearini L. Differing Expression of Enzymes of the Glyoxalase System in Superficial and Invasive Bladder Carcinomas. www.ejconline.com.
   Google Scholar
• Scui "D, Davidson JP, Cherry MS, Choudhury H, Tazaki C, Konno S. Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy. J Urol. 1999;8.
   Google Scholar
• Samadi AA, Fullerton SA, Tortorelis DG, Johnson GB, Davidson SD, Choudhury MS, Mallouh C, Tazaki H, Konno S. Glyoxalase I phenotype as a potential risk factor for prostate carcinoma. Urology. 2001;57(1):183–187.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Mashima T, Kizaki A. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood. 2000;95:3214–3218.
   Google Scholar
• Al-Balas QA, Hassan MA, Al-Shar’i NA, Al Jabal GA, Almaaytah AM. Recent advances in glyoxalase-I inhibition. Mini Rev Med Chem. 2019;19(4):281–291.
   PubMed Web of Science ®Google Scholar
• Kumar A, Voet A, Zhang KYJ. Fragment based drug design: from experimental to computational approaches. Curr Med Chem. 2012;19(30):5128–5147.
   PubMed Web of Science ®Google Scholar
• Böhm HJ. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 1992;6(1):61–78.
   PubMed Web of Science ®Google Scholar
• Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins: Structure, Function, and Genetics. 1991;11(1):29–34.
   PubMed Web of Science ®Google Scholar
• Tirado-Rives J, Jorgensen WL. Contribution of conformer focusing to the uncertainty in predicting free energies for protein − ligand binding. J Med Chem. 2006;49(20):5880–5884.
   PubMed Web of Science ®Google Scholar
• Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449–461.
   PubMed Web of Science ®Google Scholar
• Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem. 2008;51(8):2432–2438.
   PubMed Web of Science ®Google Scholar
• Böhm HJ. LUDI: rule-based automatic design of new substituents for enzyme inhibitor leads. J Comput Aided Mol Des. 1992;6(6):593–606.
   PubMed Web of Science ®Google Scholar
• Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER? A CHARMm-based MD docking algorithm. J Comput Chem. 2003;24(13):1549–1562.
   PubMed Web of Science ®Google Scholar
• Rao SN, Head MS, Kulkarni A, LaLonde JM. Validation studies of the site-directed docking program LibDock. J Chem Inf Model. 2007;47(6):2159–2171.
   PubMed Web of Science ®Google Scholar
• Cereto-Massagué A, Ojeda MJ, Valls C, Mulero M, Garcia-Vallvé S, Pujadas G. Molecular fingerprint similarity search in virtual screening. Methods. 2015;71:58–63.
   PubMed Web of Science ®Google Scholar
• Barnum D, Greene J, Smellie A, Sprague P. Identification of common functional configurations among molecules. J Chem Inf Comput Sci. 1996;36(3):563–571.
   PubMedGoogle Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–530.
   PubMedGoogle Scholar